Stannosciocalcin 1: A Promising Compound with Anti-inflammatory and Anti-tumor Effects

Target Name: STC1

NCBI ID: G6781

STC1

Stannosciocalcin 1: A Promising Compound with Anti-inflammatory and Anti-tumor Effects

Stannosciocalcin 1 (STC1) is a peptide that is found in the skin and other connective tissues. It is a small molecule that has been shown to have a variety of biological functions, including anti-inflammatory and anti-tumor effects. As a result, STC1 has potential as a drug target or biomarker.

The ability of STC1 to stimulate anti-inflammatory responses is one of its most promising properties. Chronic inflammation is a major risk factor for a variety of diseases, including heart disease, diabetes, and cancer. Therefore, compounds that can effectively reduce inflammation have the potential to be useful in treating these conditions. STC1 has been shown to have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines.

In addition to its anti-inflammatory properties, STC1 has also been shown to have anti-tumor effects. The number of cancer-related deaths continues to rise, and there is a need for new treatments to effectively target this disease. STC1 has been shown to inhibit the growth of cancer cells in a variety of models. This suggests that it may be a useful target for cancer treatment.

STC1 has also been shown to have other biological functions. For example, it has been shown to improve skin barrier function, which can help to prevent the entry of harmful substances into the skin. It also has been shown to promote wound healing, which can be beneficial in the healing process after an injury or surgery.

The potential uses of STC1 are vast, and there is ongoing research to determine its potential as a drug target or biomarker. For example, STC1 has been shown to be a potential therapeutic for the treatment of atopic dermatitis, a common form of inflammatory skin disease. In addition, STC1 has been shown to be a potential treatment for skin aging, which can be caused by a variety of factors, including inflammation and reduced skin elasticity.

In conclusion, STC1 is a promising compound with a variety of biological functions. Its anti-inflammatory and anti-tumor effects make it a potential drug target or biomarker. Further research is needed to fully understand its potential uses and to develop safe and effective treatments.

Protein Name: Stanniocalcin 1

Functions: Stimulates renal phosphate reabsorption, and could therefore prevent hypercalcemia

The "STC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets